CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitNEW YORK - October 23, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (
NASDAQ: CYTK) and certain of its officers.
Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Cytokinetics, Incorporated Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CYTKNEW YORK - October 23, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated (
NASDAQ: CYTK) of a class action securities lawsuit.
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (
NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTKNEW ORLEANS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline - CYTKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline - CYTKNEW YORK - October 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated (
NASDAQ: CYTK) of a class action securities lawsuit.
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTKNEW YORK and NEW ORLEANS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Contact Levi & Korsinsky by November 17, 2025 Deadline to Join Class Action Against Cytokinetics, Incorporated (CYTK)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Contact Levi & Korsinsky by November 17, 2025 Deadline to Join Class Action Against Cytokinetics, Incorporated (CYTK)NEW YORK - October 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated (
NASDAQ: CYTK) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTKNEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (
NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTKNEW YORK - October 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated (
NASDAQ: CYTK) of a class action securities lawsuit.
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action LawsuitNEW YORK - October 17, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (
NASDAQ: CYTK) and certain of its officers.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTKNEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (
NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTKFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTKNEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action LawsuitsNEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of V.F. Corporation (
NYSE:VFC), Cytokinetics, Incorporated (
NASDAQ:CYTK), Quanex Building Products Corporation (
NYSE:NX), and RCI Hospitality Holdings, Inc. (
NASDAQ:RICK). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
